Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

19.67 +0.46 (+2.39%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist

Price and Volume

Volume	2,148,963
Open	19.25
Bid (Size)	19.67 (1,200)
Ask (Size)	19.70 (300)
Prev. Close	19.21
Today's Range	19.04 - 20.02
52wk Range	8.010 - 25.00
Shares Outstanding	58,310,703
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

April 01, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗

March 21, 2026

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

Via The Motley Fool

Performance

YTD	+6.3%	+6.3%
1 Month	+10.1%	+10.1%
3 Month	+18.6%	+18.6%
6 Month	+17.4%	+17.4%
1 Year	+110.8%	+110.8%

More News

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

March 08, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

March 08, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗

March 02, 2026

Via Chartmill

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Via The Motley Fool

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 02, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Participate in Upcoming Investor Conferences

February 25, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

February 22, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

January 20, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

December 23, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

December 11, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Dyne Therapeutics Stock Was a Big Winner on Wednesday ↗

December 10, 2025

Via The Motley Fool

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

December 09, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Dyne Therapeutics Stock Tanked on Tuesday ↗

December 09, 2025

Via The Motley Fool

Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More ↗

December 09, 2025

Via The Motley Fool

Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears

December 09, 2025

Via MarketMinute

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

Via The Motley Fool

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

Via The Motley Fool

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

December 08, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

December 08, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

December 07, 2025

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Via The Motley Fool

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?

Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?

Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?

The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market

What is the current price of Dyne Therapeutics, Inc. - Common Stock?

The current price of Dyne Therapeutics, Inc. - Common Stock is 19.67

When was Dyne Therapeutics, Inc. - Common Stock last traded?

The last trade of Dyne Therapeutics, Inc. - Common Stock was at 04/22/26 04:00 PM ET

What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?

The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 1.15B

How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?

Dyne Therapeutics, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.